Research on Ilika plc (IKA:LON)  from Morphose Capital Partners

Ilika’s financial year-end is April. Today it updated on period trading, alongside full-year results notice for July 29th. Numbers will be broadly in-line; topline & ebitda slightly behind at £1.1m & (£6.2m) respectively & key closing cash ahead at £5.3m c.f. £5.0m. Trading activity for both Stereax & Goliath solid state battery (SSB) platforms was positive. Stereax™ generated first genuine commercial revenue of £100K from Cirtec medical for delivery of its 1st electrode batch in March, a symbolic milestone. Goliath cells scaled from 2Ah to 10Ah at UKBIC, with increasing quality evinced by increased OEM engagement in EVs & new verticals defence with several companies & e-bikes with blue-chip Brompton Cycles.

View Full Research